Celldex Therapeutics (CLDX) Total Current Liabilities (2010 - 2026)

Celldex Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $51.5 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 60.76% year-over-year to $51.5 million in Q1 2026; TTM through Mar 2026 was $51.5 million, a 60.76% increase from a year earlier, with the FY2025 full-year figure at $51.0 million, up 29.09% from the prior year.
• Total Current Liabilities climbed to $51.5 million in Q1 2026 per CLDX's latest filing, from $51.0 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $51.5 million in Q1 2026 and bottomed at $14.6 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $29.9 million (2022), against an average of $29.9 million.
• Across the five-year window, Total Current Liabilities surged 106.72% in 2022 and tumbled 47.76% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $18.6 million in 2022, then soared by 67.25% to $31.1 million in 2023, then increased by 26.91% to $39.5 million in 2024, then increased by 29.09% to $51.0 million in 2025, then advanced by 0.94% to $51.5 million in 2026.
• Per Business Quant, the three latest CLDX Total Current Liabilities figures stand at $51.5 million (Q1 2026), $51.0 million (Q4 2025), and $46.5 million (Q3 2025).